Contrave
Loading...Contrave Recall
Get an alert when a recall is issued.
Questions & Answers
Side Effects & Adverse Reactions
There is currently no warning information available for this product. We apologize for any inconvenience.
Legal Issues
There is currently no legal information available for this drug.
FDA Safety Alerts
There are currently no FDA safety alerts available for this drug.
Manufacturer Warnings
There is currently no manufacturer warning information available for this drug.
FDA Labeling Changes
There are currently no FDA labeling changes available for this drug.
Uses
CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
- •
- 30 kg/m 2 or greater (obese) or
- •
- 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
Limitations of Use:
- •
- The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established.
- •
- The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
History
There is currently no drug history available for this drug.
Other Information
CONTRAVE extended-release tablets contain naltrexone hydrochloride and bupropion hydrochloride.
Naltrexone hydrochloride, USP, an opioid antagonist, is a synthetic congener of oxymorphone with no opioid agonist properties. Naltrexone differs in structure from oxymorphone in that the methyl group on the nitrogen atom is replaced by a cyclopropylmethyl group. Naltrexone hydrochloride is also related to the potent opioid antagonist, naloxone, or n-allylnoroxymorphone.
Naltrexone hydrochloride has the chemical name of morphinan-6-one, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxy-, hydrochloride, (5α)-. The empirical formula is C20H23NO4•HCl and the molecular weight is 377.86. The structural formula is:
Naltrexone hydrochloride is a white to yellowish, crystalline compound. It is soluble in water to the extent of about 100 mg/mL.
Bupropion hydrochloride is an antidepressant of the aminoketone class. Bupropion hydrochloride closely resembles the structure of diethylpropion. It is designated as (±)-1-(3 chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propranone hydrochloride. It is related to phenylethylamines. The empirical formula is C13H18ClNO•HCl and the molecular weight is 276.2. The structural formula is:
Bupropion hydrochloride powder is white, crystalline, and highly soluble in water.
CONTRAVE is available for oral administration as a round, bi-convex, film-coated, extended-release tablet. Each tablet has a trilayer core composed of two drug layers, containing the drug and excipients, separated by a more rapidly dissolving inert layer. Each tablet contains 8 mg of naltrexone hydrochloride and 90 mg of bupropion hydrochloride. Tablets are blue and are debossed with NB-890 on one side. Each tablet contains the following inactive ingredients: microcrystalline cellulose, hydroxypropyl cellulose, lactose anhydrous, L-cysteine hydrochloride, crospovidone, magnesium stearate, hypromellose, edetate disodium, lactose monohydrate, colloidal silicon dioxide, Opadry II Blue and FD&C Blue #2 aluminum lake.
Sources
Contrave Manufacturers
-
Takeda Pharmaceuticals America, Inc.
![Contrave (Naltrexone Hydrochloride And Bupropion Hydrochloride) Tablet, Film Coated, Extended Release [Takeda Pharmaceuticals America, Inc.]](/wp-content/themes/bootstrap/assets/img/loading2.gif)
Contrave | Takeda Pharmaceuticals America, Inc.
2.1 Recommended DosingCONTRAVE dosing should be escalated according to the following schedule:
Morning Dose
Evening Dose
Week 1
1 tablet
None
Week 2
1 tablet
1 tablet
Week 3
2 tablets
1 tablet
Week 4 – Onward
2 tablets
2 tablets
A total daily dosage of two CONTRAVE 8 mg/90 mg tablets twice daily (32 mg/360 mg) is reached at the start of Week 4.
CONTRAVE should be taken by mouth in the morning and in the evening. The tablets should not be cut, chewed, or crushed. Total daily doses greater than 32 mg/360 mg per day (two tablets twice daily) are not recommended. In clinical trials, CONTRAVE was administered with meals. However, CONTRAVE should not be taken with a high-fat meal because of a resulting significant increase in bupropion and naltrexone systemic exposure [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
Patients may develop elevated blood pressure or heart rate during CONTRAVE treatment; the risk may be greater during the initial three months of therapy [see Warnings and Precautions (5.6)]. Because patients with hypertension may be at increased risk for developing blood pressure elevations, such patients should be monitored for this potential effect when initiating treatment with CONTRAVE.
Response to therapy should be evaluated after 12 weeks at the maintenance dosage. If a patient has not lost at least 5% of baseline body weight, discontinue CONTRAVE, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.
BMI is calculated by dividing weight (in kg) by height (in meters) squared. A BMI chart for determining BMI based on height and weight is provided in Table 1.
Table 1. BMI Conversion Chart
Weight
(lb)
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
(kg)
56.8
59.1
61.4
63.6
65.9
68.2
70.5
72.7
75.0
77.3
79.5
81.8
84.1
86.4
88.6
90.9
93.2
95.5
97.7
100. 0
102. 3
Height
(in)
(cm)
58
147.3
26
27
28
29
30
31
32
34
35
36
37
38
39
40
41
42
43
44
45
46
47
59
149.9
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
43
44
45
46
60
152.4
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
61
154.9
24
25
26
27
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
62
157.5
23
24
25
26
27
27
28
29
30
31
32
33
34
35
36
37
38
38
39
40
41
63
160.0
22
23
24
25
26
27
28
28
29
30
31
32
33
34
35
36
36
37
38
39
40
64
162.6
22
22
23
24
25
26
27
28
28
29
30
31
32
33
34
34
35
36
37
38
39
65
165.1
21
22
23
23
24
25
26
27
28
28
29
30
31
32
33
33
34
35
36
37
38
66
167.6
20
21
22
23
23
24
25
26
27
27
28
29
30
31
32
32
33
34
35
36
36
67
170.2
20
20
21
22
23
24
24
25
26
27
27
28
29
30
31
31
32
33
34
35
35
68
172.7
19
20
21
21
22
23
24
24
25
26
27
27
28
29
30
30
31
32
33
34
34
69
175.3
18
19
20
21
21
22
23
24
24
25
26
27
27
28
29
30
30
31
32
33
33
70
177.8
18
19
19
20
21
22
22
23
24
24
25
26
27
27
28
29
29
30
31
32
32
71
180.3
17
18
19
20
20
21
22
22
23
24
24
25
26
27
27
28
29
29
30
31
31
72
182.9
17
18
18
19
20
20
21
22
22
23
24
24
25
26
27
27
28
29
29
30
31
73
185.4
17
17
18
19
19
20
20
21
22
22
23
24
24
25
26
26
27
28
28
29
30
74
188.0
16
17
17
18
19
19
20
21
21
22
23
23
24
24
25
26
26
27
28
28
29
75
190.5
16
16
17
18
18
19
19
20
21
21
22
23
23
24
24
25
26
26
27
28
28
76
193.0
15
16
16
17
18
18
19
20
20
21
21
22
23
23
24
24
25
26
26
27
27
2.2 Dose Adjustment in Patients with Renal ImpairmentIn patients with moderate or severe renal impairment, the maximum recommended daily dose for CONTRAVE is two tablets (one tablet each morning and evening). CONTRAVE is not recommended for use in patients with end-stage renal disease. There is a lack of adequate information to guide dosing in patients with mild renal impairment [see Use in Specific Population (8.6) and Clinical Pharmacology (12.3)].
2.3 Dose Adjustment in Patients with Hepatic ImpairmentIn patients with hepatic impairment, the maximum recommended daily dose of CONTRAVE is one tablet in the morning [see Use in Specific Population (8.7) and Clinical Pharmacology (12.3)].
2.4 Switching a Patient To or From a Monoamine Oxidase Inhibitor (MAOI) AntidepressantAt least 14 days should elapse between discontinuation of an MAOI intended to treat depression and initiation of therapy with CONTRAVE. Conversely, at least 14 days should be allowed after stopping CONTRAVE before starting an MAOI antidepressant [see Contraindications (4) and Drug Interactions (7.1)].
2.5 Concomitant Use with CYP2B6 InhibitorsDuring concomitant use with CYP2B6 inhibitors (e.g., ticlopidine or clopidogrel), the maximum recommended daily dose of CONTRAVE is two tablets (one tablet each morning and evening) [see Drug Interactions (7.4) and Clinical Pharmacology (12.3)].
Login To Your Free Account